We are live on ! Find out more
DYN icon

Dyne Therapeutics
DYN

227 hedge funds and large institutions have $3.4B invested in Dyne Therapeutics in 2026 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 100 increasing their positions, 60 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 60

2% less capital invested

Capital invested by funds: $3.48B → $3.4B (-$78.1M)

7% less first-time investments, than exits

New positions opened: 42 | Existing positions closed: 45

2% less funds holding

Funds holding: 232 → 227 (-5)

10.74% less ownership

Funds ownership: 124.57% → 113.83% (-11%)

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

83% less call options, than puts

Call options by funds: $769K | Put options by funds: $4.47M

Holders
227
Holders Change
-5
Holders Change %
-2.16%
% of All Funds
2.79%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.06%
New
42
Increased
100
Reduced
60
Closed
45
Calls
$769K
Puts
$4.47M
Net Calls
-$3.7M
Net Calls Change
-$596K

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$228M
2
VPC
Vestal Point Capital
New York
+$66.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$40.3M
4
OAG
Orbis Allan Gray
Bermuda
+$33.8M
5
Fiera Capital (Canada)
Fiera Capital (Canada)
Quebec, Canada
+$23.8M

Top Sellers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$71.9M
2
SL
Siren LLC
Connecticut
-$22M
3
CS
Candriam SCA
Luxembourg
-$20.7M
4
VC
Vivo Capital
California
-$18.2M
5
Citadel Advisors
Citadel Advisors
Florida
-$16.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Investment Management
1
T. Rowe Price Investment Management
Maryland
$558M +$228M +13,245,712 +76%
Janus Henderson Group
2
Janus Henderson Group
United Kingdom
$247M -$4.14M -240,346 -2%
BlackRock
3
BlackRock
New York
$212M +$8.78M +509,032 +5%
AVLSA
4
Atlas Venture Life Science Advisors
Massachusetts
$166M – – –
Fidelity Investments
5
Fidelity Investments
Massachusetts
$162M +$40.3M +2,339,059 +36%
OAG
6
Orbis Allan Gray
Bermuda
$123M +$33.8M +1,960,303 +41%
State Street
7
State Street
Massachusetts
$121M -$672K -38,999 -0.6%
VCM
8
Vanguard Capital Management
Pennsylvania
$116M +$110M +6,405,069 New
PA
9
Perceptive Advisors
New York
$84.6M +$20.5M +1,189,895 +34%
FIS
10
FCPM III Services
Netherlands
$84.2M -$14.1M -818,460 -15%
TCM
11
TCG Crossover Management
California
$83.7M – – –
VPM
12
Vanguard Portfolio Management
Pennsylvania
$75.5M +$71.8M +4,162,041 New
VPC
13
Vestal Point Capital
New York
$72.5M +$66.9M +3,880,000 +3,233%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$63.5M +$4.15M +240,685 +7%
AC
15
Armistice Capital
New York
$57.6M -$1.29M -74,598 -2%
FLSM
16
Frazier Life Sciences Management
California
$57.2M – – –
JP Morgan Chase
17
JP Morgan Chase
New York
$55.6M -$5.11M -296,436 -8%
O
18
OrbiMed
New York
$52.9M +$12.3M +715,700 +32%
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$42.2M +$79K +4,584 +0.2%
SL
20
Siren LLC
Connecticut
$40.4M -$22M -1,273,816 -36%
VA
21
VR Adviser
New York
$39.4M – – –
Franklin Resources
22
Franklin Resources
California
$36.4M +$42.1K +2,444 +0.1%
DTC
23
Deep Track Capital
Connecticut
$36.3M -$11.2M -650,000 -25%
SC
24
Samlyn Capital
New York
$34.9M +$7.41M +429,468 +29%
Goldman Sachs
25
Goldman Sachs
New York
$31.2M -$9.66M -560,075 -25%
1
2 3 4 5

DYN Hedge Fund Activity: Q1 2026 in Review

227 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q1 2026, worth a combined $3.4B — down 2.2% from $3.48B a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of DYN and 42 opened new positions — a net loss of 3 holders — while 60 trimmed existing stakes and 100 added.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $228M. The largest seller was Adage Capital Partners, cutting an estimated $71.9M.

  • 227 institutional investors held Dyne Therapeutics (DYN) as of Q1 2026, down from 232 in Q4 2025.
  • Funds reported $3.4B of Dyne Therapeutics stock for Q1 2026, down 2.2% quarter-over-quarter.
  • 42 funds opened new Dyne Therapeutics positions in Q1 2026 and 45 closed out, a net change of -3 holders.
  • The largest Dyne Therapeutics buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $228M added.
  • The largest Dyne Therapeutics seller in Q1 2026 was Adage Capital Partners, an estimated $71.9M sold.

Based on aggregated 13F filings for Q1 2026.